Linked Life Data

1911202

Source:http://linkedlifedata.com/resource/pubmed/id/1911202

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1991-10-31
pubmed:abstractText
Forty-four children aged 3-13 years with Murphy stage III B cell non-Hodgkin's lymphoma were treated between May 1986 and December 1989. All have been followed up for at least 12 months. The primary site was the abdomen in 37 children, 24 of whom had involvement of other organs or nodal disease outside the abdomen. Twenty-eight received a standard dose regimen (regimen 1) and 16 had a more intensive regimen (regimen 2--MACHO). Fourteen patients (87%) who received MACHO had extensive multi-organ disease compared to 15 (53%) on regimen 1. Most of the latter had only pleural effusions. Thirty-four children are alive relapse free and considering the early relapse pattern in this disease are probably cured (actuarial event free survival = 76%). There has been one relapse (6%) after MACHO, but three toxic deaths. Six patients (21%) on the less intensive regimen have relapsed. Morbidity was high in terms of infection and need for haematological support and hospitalisation in the one third of children electively given the more intensive regimen. It is concluded that the vast majority of children with stage III disease who have disease limited to lymph nodes are curable with a moderately intensive regimen. Those with multiorgan involvement probably require more intensive treatment. It is therefore of importance to clarify prognostic factors in these patients to determine who can be cured with a less intensive regimen and who requires further dose intensification.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/1911202-2913472, http://linkedlifedata.com/resource/pubmed/commentcorrection/1911202-2915234, http://linkedlifedata.com/resource/pubmed/commentcorrection/1911202-2930714, http://linkedlifedata.com/resource/pubmed/commentcorrection/1911202-3128648, http://linkedlifedata.com/resource/pubmed/commentcorrection/1911202-3491184, http://linkedlifedata.com/resource/pubmed/commentcorrection/1911202-3493799, http://linkedlifedata.com/resource/pubmed/commentcorrection/1911202-3525767, http://linkedlifedata.com/resource/pubmed/commentcorrection/1911202-3572462, http://linkedlifedata.com/resource/pubmed/commentcorrection/1911202-3896295, http://linkedlifedata.com/resource/pubmed/commentcorrection/1911202-455324, http://linkedlifedata.com/resource/pubmed/commentcorrection/1911202-6338381, http://linkedlifedata.com/resource/pubmed/commentcorrection/1911202-6689423, http://linkedlifedata.com/resource/pubmed/commentcorrection/1911202-7414342
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0007-0920
pubmed:author
pubmed:issnType
Print
pubmed:volume
64
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
583-7
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1991
pubmed:articleTitle
Outcome in stage III non-Hodgkin's lymphoma in children (UKCCSG study NHL 86)--how much treatment is needed? United Kingdom Children's Cancer Study Group.
pubmed:affiliation
Children's Unit, Royal Marsden Hospital, Sutton, UK.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Research Support, Non-U.S. Gov't